The window
is open.
Not for long.
KRECE is building the first documented, pharmaceutical-grade peptide protocol platform in Latin America — a $200B global longevity market with virtually no quality player in a region of 650 million people. We are not entering a crowded market. We are creating a category.
The market exists.
The supply doesn't.
Latin America has sophisticated demand for precision longevity — functional medicine physicians, anti-aging clinics, biohackers with purchasing power. What does not exist is a quality-documented supply chain that meets their needs. That gap is KRECE's entire market opportunity. The TAM is global. The SAM is underserved. The SOM is ours to define.
Too early was
2020. Too late
will be 2028.
The longevity market in Latin America has been building demand for a decade. What it has lacked is a player with the operational infrastructure, regulatory knowledge and quality standards to supply it professionally. That infrastructure is being built now — by KRECE.
Three structural events converge in 2026 that create a window that will close. Miss it and you're funding the second player.
Progressive elimination of tariffs on pharmaceutical and cosmetic ingredients between Europe and MERCOSUR markets. KRECE operates on both sides of this agreement — Tarragona + Asunción. Structural cost advantage that grows over 10 years as the tariff schedule phases in.
September 2024: NA-Selank, NA-Semax, CJC-1295, Ipamorelin, TA-1 removed from FDA prohibited compounding list. Signal to the global market that these compounds have earned scientific credibility — accelerating adoption in LATAM and Europe simultaneously.
The North American market is consolidating around Halo Health, Ro, and direct-to-consumer platforms. None of them are building for LATAM. The window to establish category leadership before US or European players enter is measured in 18–24 months, not years.
KRECE LLC (Wisconsin) · ESB22582993 (Spain) · KRECE Innovación S.A. (Paraguay). Most competitors operate from one jurisdiction. KRECE's three-entity structure provides regulatory optionality, currency diversification, and access to three distinct legal frameworks simultaneously.
The competitors
don't operate
where we do.
KRECE does not compete with US peptide companies — they don't serve LATAM at quality level. It does not compete with LATAM supplement brands — they lack documentation. It does not compete with pharmaceutical companies — the price point is inaccessible. KRECE occupies uncontested space. That is not a claim. It is a competitive map.
Product today.
Platform tomorrow.
KRECE's revenue model is designed to compound. It starts with high-margin B2B product sales and expands into licensing, brand labelling and a proprietary AI personalization platform — each layer adding defensibility and margin expansion. The trajectory is not linear. It is exponential by design.
Venta directa de protocolos SIGNALS a clínicas, médicos y consumidor premium. $90–$300 USD por unidad. Modelo de suscripción para rotación de protocolos con endpoints de biomarcadores.
Licencias del sistema de protocolos y brand labelling para clínicas y marcas complementarias. Fee inicial + royalty por volumen. Alta escalabilidad, coste marginal mínimo una vez desarrollado el protocolo.
Motor de personalización por IA para médicos: entrada de biomarcadores, generación de protocolo individualizado, seguimiento y ajuste. Modelo SaaS recurrente mensual por médico/clínica. El activo de mayor defensibilidad del grupo.
An engineer found
a broken system
and fixed it.
Most longevity founders come from medicine or marketing. Physicians understand the biology but struggle to build scalable quality systems. Marketers know how to sell but don't always understand the product. Ignacio Rubio is an industrial engineer with degrees in economics and marketing — the rare profile that understands the system, the market and the communication simultaneously.
KRECE was not built from inspiration. It was built from a cold engineering analysis of where the quality system failed in the longevity supply chain — and from the conviction that the people who believe in science deserve products that respect it.
Industrial engineer with formal degrees in economics and marketing. Operating from three jurisdictions simultaneously. Track record in channel development, licensing and strategic partnerships. Applying industrial process engineering methodology to precision longevity.
KRECE LLC (USA) + ESB22582993 (Spain) + Paraguay entity gives regulatory optionality that no single-jurisdiction competitor can replicate quickly. Building this infrastructure takes 12–18 months minimum. It is already built.
When KRECE establishes independent CoA verification as the expected standard in LATAM, every competitor without it is automatically positioned as inferior. The moat is not just KRECE's quality — it is KRECE defining what quality means in the market.
Every patient protocol generates biomarker data. That data trains KREC.IA to personalize future protocols. More patients → better AI → better outcomes → more patients. This flywheel does not exist in any LATAM competitor because none have started collecting this data.
KRECE is pre-positioned on both sides of the EU-MERCOSUR agreement. As tariffs reduce over 10 years, KRECE's European supply chain becomes progressively cheaper relative to any competitor sourcing outside the agreement. This advantage compounds annually.
The probability is small.
The possibility is real.
We are not promising a unicorn. We are building in a market where unicorns already exist — and they are all American or European. No one has built the dominant longevity platform for 650 million Spanish-speaking people. The company that does will be valued accordingly. The question is not whether this market produces a unicorn. It already is. The question is who captures it.
The North American market consolidated while the window was open. The LATAM window is open now. The investors who built positions in Hims & Hers, Ro and Thorne in their earliest rounds understood this. The LATAM precision longevity category is at that exact moment.
The full investor presentation includes detailed financial projections, unit economics per market, go-to-market timeline, competitive analysis and use of funds. Available under NDA to qualified investors and VCs. Response within 48 hours. If you are a strategic investor with LATAM distribution or pharma/biotech background, please mention it — prioritized review.
For investors who prefer to start with a direct conversation before any documentation. 30-minute video call with the founder — no pitch deck, no formalities. Just a conversation about the market, the thesis, the team and whether there is alignment. Strategic investors, angels, family offices and VCs with LATAM or biotech focus especially welcome.
This page contains forward-looking statements and projections based on current market data, management assumptions and industry analysis. Market size figures sourced from publicly available industry reports (Grand View Research, MarketsandMarkets, WHO longevity data, 2024–2025). Comparable company valuations are reference points for market context, not guarantees of future performance. KRECE LLC is a pre-revenue stage company. Investment in early-stage companies carries significant risk including total loss of capital. This page does not constitute a securities offering. Full risk disclosure available in the investor deck under NDA. KRECE LLC · Wisconsin, USA · hq@krece.io